$9.22
2.54% yesterday
Nasdaq, Jun 27, 10:03 pm CET
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Ocular Therapeutix Inc Stock price

$9.22
+2.28 32.85% 1M
+0.78 9.24% 6M
+0.68 7.96% YTD
+2.46 36.39% 1Y
+5.11 124.33% 3Y
+0.94 11.35% 5Y
-12.22 57.00% 10Y
-3.93 29.89% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.24 2.54%
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.2b
Net debt
$-280.5m
Cash
$349.7m
Shares outstanding
159.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
24.62 | 25.63
EV/Sales
19.92 | 20.73
EV/FCF
negative
P/B
5.52
Financial Health
Equity Ratio
68.86%
Return on Equity
-61.36%
ROCE
-55.46%
ROIC
-
Debt/Equity
0.26
Financials (TTM | estimate)
Revenue
$59.7m | $57.3m
EBITDA
$-200.2m | $-188.0m
EBIT
$-204.1m
Net Income
$-192.7m | $-229.9m
Free Cash Flow
$-148.4m
Growth (TTM | estimate)
Revenue
-0.33% | -10.06%
EBITDA
-127.48% | -11.90%
EBIT
-123.17%
Net Income
-67.18% | -18.83%
Free Cash Flow
-70.39%
Margin (TTM | estimate)
Gross
90.67%
EBITDA
-335.70% | -328.05%
EBIT
-342.15%
Net
-323.09% | -401.24%
Free Cash Flow
-248.85%
More
EPS
$-1.15
FCF per Share
$-0.93
Short interest
9.09%
Employees
274.00
Rev per Employee
$230.00k
Show more

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Ocular Therapeutix Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
94%
Hold
6%

Financial data from Ocular Therapeutix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
60 60
0% 0%
100%
- Direct Costs 5.56 5.56
3% 3%
9%
54 54
1% 1%
91%
- Selling and Administrative Expenses 108 108
37% 37%
182%
- Research and Development Expense 150 150
123% 123%
251%
-200 -200
127% 127%
-336%
- Depreciation and Amortization 3.85 3.85
13% 13%
6%
EBIT (Operating Income) EBIT -204 -204
123% 123%
-342%
Net Profit -193 -193
67% 67%
-323%

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
GlobeNewsWire
2 days ago
The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience
Neutral
GlobeNewsWire
12 days ago
BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV.
Neutral
GlobeNewsWire
about 2 months ago
BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025.
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Pravin Dugel
Employees 274
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today